EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2026

(LOSS) EARNINGS PER SHARE

(Loss) Earnings per share were as follows (amounts in thousands, except per share data):


	Three months ended				Nine months ended
	September 30,				September 30,
	2026		2025		2026		2025
Net loss from continuing operations	$	(8,801)	$	(7,725)	$	(37,792)	$	(18,407)

Net (loss) income from discontinued operations, net of tax	$	(33,650)	$	5,266	$	(22,569)	$	12,366

Net loss attributable to Titan and applicable to common shareholders	$	(42,744)	$	(2,262)	$	(61,194)	$	(7,456)

Determination of shares:
Weighted average shares outstanding for continuing operations and total Titan (basic)	64,463		63,895		64,334		63,635
Effect of restricted stock and stock options	—		—		—		—
Weighted average shares outstanding for continuing operations and total Titan (diluted)	64,463		63,895		64,334		63,635

Weighted average shares outstanding for discontinued operations (basic)	64,463		63,895		64,334		63,635
Effect of restricted stock and stock options	—		172		—		269
Weighted average shares outstanding for discontinued operations (diluted)	64,463		64,067		64,334		63,904

Basic (loss) earnings per common share:
Continuing operations	$	(0.14)	$	(0.12)	$	(0.59)	$	(0.29)
Discontinued operations	(0.52)		0.08		(0.35)		0.19
Net loss per share attributable to Titan and applicable common stockholders	(0.66)		(0.04)		(0.95)		(0.12)

Diluted (loss) earnings per common share:
Continuing operations	$	(0.14)	$	(0.12)	$	(0.59)	$	(0.29)
Discontinued operations	(0.52)		0.08		(0.35)		0.19
Net loss per share attributable to Titan and applicable common stockholders	(0.66)		(0.04)		(0.95)		(0.12)

The effect of restricted stock and stock options has been excluded for the calculation of diluted loss per common share for continuing operations, discontinued operations, and total Titan the three and nine months ended September 30, 2026, as the effect would have been antidilutive. The weighted average shares excluded for equity awards for the three and nine months ended September 30, 2026 was 0.1 million and 0.2 million, respectively.

The effect of restricted stock and stock options was excluded from the calculation of diluted loss per common share for both continuing operations and total Titan for the three and nine months ended September 30, 2025, as the effect would have been antidilutive. The weighted average shares excluded for equity awards for the three and nine months ended September 30, 2025 was 0.2 million and 0.3 million, respectively.